Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery (CLIO)

Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery

This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer.

EnLightTM will be used to detect positron emission and the LightPathTM system to detect Cerenkov Luminescence. Both are emitted by the Positron Emission Tomography (PET) agent.

The study will also evaluate the patient safety and radiation safety of the EnLightTM, and the safety for the device operators and surgical staff of the LightPathTM Imaging System.

Study Overview

• Status: Withdrawn
• Conditions: Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer; Duodenal Cancer
• Intervention / Treatment: Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose; Device: EnLightTM; Device: LightPathTM Imaging System

Detailed Description

This is a pilot study that is prospective, open-label, single-centre in nature in patients with gastric, pancreas, bile duct or duodenal cancer in whom tumour excision surgery is indicated.

Patients who give written informed consent will be screened for the study (Visit 1). Patients will undergo a positron emission tomography (PET) whole body scan. Screening assessments, including the PET scan, must be performed no less than 60 days before surgery and may be performed on the day of surgery.

On the day of surgery (Visit 2), subject's blood glucose level will be measured. Subjects with a blood glucose level < 12 mmol/l will receive an intravenous injection of 2-5 Mega Becquerel/kg (MBq/kg), up to a maximum 300 MBq of fluorine-18 fluorodeoxyglucose (18F-FDG) prior to surgery.

During surgery and not less than 120 minutes after injection of FDG, the primary lesion will be imaged using the EnLightTM system to determine margin status.

Gastrointestinal tumour excision surgery will then be performed according to standard of care. The surgical cavity and the lymph nodes will be imaged by the EnLightTM system to establish whether other radioactive tissue remain. These results will not influence any surgical or clinical decision-making, which will remain as standard of care. The resected tumour excision specimen will be imaged by the LightPathTM Imaging System. The resected tumour excision specimen will, in addition, be analysed according to standard of care pathology. The surgeon and surgical staff will be monitored for external exposure to ionizing radiation by means of dosimeters, and position sensors during surgery.

Patients will be followed-up (Visit 3) within a 2 - 14 day window after the end of surgery for adverse events (AEs). Those related to the use of the investigational devices, or the PET imaging agent will be identified as such.

• Study Type: Observational

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary
    • Semmelweis University First Clinic of Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Female or male patients aged ≥ 30 years diagnosed with gastric, pancreatic, bile duct or duodenal cancer, whose treatment is to be tumour excision surgery.

Description

Inclusion Criteria:

1. Provides written informed consent to participate in the study.
2. Is a man or woman aged ≥ 30 years.
3. Patients diagnosed with gastric, pancreatic, bile duct or duodenal cancer whose treatment is to be tumour excision surgery.
4. Life expectancy of at least 12 months.
5. Blood glucose level < 12 mmol/l.

Exclusion Criteria:

1. Participation in another clinical study either concurrently or within 180 days prior to surgery.
2. Major surgery within 30 days before the baseline visit.
3. Women who are pregnant or lactating.
4. Renal impairment, hepatic impairment, serious infection or other life-threatening illness, other than cancer, within 60 days before surgery.
5. Previous exposure to ionizing radiation >5 millisieverts (mSv) in the previous 12 months.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

EnLightTM and LightPathTM Imaging Systems arm; Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care. The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs).

Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose; The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems; Other Names: FDG; Device: EnLightTM; The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.; Device: LightPathTM Imaging System; The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The location of PET imaging agent as measured by beta particle detection	The EnLightTM will be used for determining the number of lesions, their location and margin status, in the surgical cavity including within surrounding tissue, and lymph nodes. The EnLightTM is a beta particle detector used for imaging the location of the PET imaging agent. It works both in a hot-spot mode, to localise areas with high beta particle detection signal from the PET imaging agent, and in an imaging mode that allows video imaging of areas where the PET imaging agent has accumulated.	Intraoperatively (during the single session of surgery on Day 0)
The location of PET imaging agent as measured by the LightPathTM Imaging System	The LightPathTM Imaging System will be used for determining the margin status of lesions and the metastatic involvement of lymph nodes.	Intraoperatively (during the single session of surgery on Day 0)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of lesions by histopathology	Number of lesions according to standard of care histopathology.	Expected on average Day 10 after surgery
The number of metastatic lymph nodes by histopathology	The number of metastatic lymph nodes according to standard of care histopathology.	Expected on average Day 10 after surgery
The extent of resection margins by histopathology	Extent of resection margins according to standard of care histopathology.	Expected on average Day 10 after surgery
Ease of use measured by questionnaire	Ease of use measured by study-specific questionnaire	At the end of imaging on Day 0
Radiation exposure	Radiological dose in microsieverts as measured by dosimeters worn by operating room staff	At the time of discharge to the ward after surgery on Day 0
Number of participants with adverse events	Patients will be followed-up until Visit 3, 2-14 days after the end of surgery on Day 0 for adverse events	Visit 3, at day 3-15

Collaborators and Investigators

• Sponsor: Lightpoint Medical Limited
• Collaborators: Semmelweis University
• Investigators: Study Director: Sheryl O'Farrell, PhD, Head of Clinical Development

Study record dates

Study Major Dates

• Study Start: December 7, 2022
• Primary Completion (Actual): January 1, 2016
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: April 27, 2015
• First Submitted That Met QC Criteria: May 13, 2015
• First Posted (Estimate): May 18, 2015

Study Record Updates

• Last Update Posted (Estimate): January 26, 2017
• Last Update Submitted That Met QC Criteria: January 25, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Duodenal Diseases; Biliary Tract Diseases; Bile Duct Diseases; Biliary Tract Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Duodenal Neoplasms; Molecular Mechanisms of Pharmacological Action; Radiopharmaceuticals; Fluorodeoxyglucose F18
• Other Study ID Numbers: LPM-005

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No